Correspondence | Published:

Making the biotech IPO work

Nature Biotechnology volume 31, pages 969970 (2013) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Innovation: The Attacker's Advantage (Summit Books, New York; 1986).

  2. 2.

    & The Innovator's Solution: Creating and Sustaining Successful Growth (Harvard Business School Press, Boston; 2003).

  3. 3.

    & Nat. Biotechnol. 30, 937–943 (2012).

  4. 4.

    , , & Clin. Pharmacol. Ther. 87, 272–277 (2010).

  5. 5.

    , & Nat. Rev. Cancer 4, 361–370 (2004).

  6. 6.

    Nat. Biotechnol. 29, 121–128 (2011).

  7. 7.

    Proc. Natl. Acad. Sci. USA 93, 12725–12730 (1996).

  8. 8.

    Science Business: the Promise, the Reality, and the Future of Biotech (Harvard Business School Press, Boston; 2006).

  9. 9.

    & Organizational Scope and Investment: Evidence from the Drug Development Strategies of Biopharmaceutical Firms. NBER working paper 10933 (National Bureau of Economic Research, 2004).

Download references

Author information

Affiliations

  1. Laura McNamee and Fred Ledley are at the Center for Integration of Science and Industry, Bentley University, Waltham, Massachusetts, USA.

    • Laura McNamee
    •  & Fred Ledley

Authors

  1. Search for Laura McNamee in:

  2. Search for Fred Ledley in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Fred Ledley.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.2711

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing